SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Berliner Dominik) "

Sökning: WFRF:(Berliner Dominik)

  • Resultat 1-2 av 2
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Deubner, Nikolas, et al. (författare)
  • Cardiac beta1-adrenoceptor autoantibodies in human heart disease: rationale and design of the Etiology, Titre-Course, and Survival (ETiCS) Study.
  • 2010
  • Ingår i: European journal of heart failure : journal of the Working Group on Heart Failure of the European Society of Cardiology. - : Wiley. - 1879-0844. ; 12:7, s. 753-62
  • Tidskriftsartikel (refereegranskat)abstract
    • Evidence for a pathophysiologic relevance of autoimmunity in human heart disease has substantially increased over the past years. Conformational autoantibodies stimulating the cardiac beta1-adrenoceptor (beta1-aabs) are considered of importance in heart failure development and clinical pilot studies have shown their prognostic significance in human 'idiopathic' cardiomyopathy.
  •  
2.
  • Pfeffer, Tobias J., et al. (författare)
  • Increased Cancer Prevalence in Peripartum Cardiomyopathy
  • 2019
  • Ingår i: JACC: CARDIOONCOLOGY. - : Elsevier BV. - 2666-0873. ; 1:2, s. 196-205
  • Tidskriftsartikel (refereegranskat)abstract
    • OBJECTIVES This study was designed to analyze the prevalence and potential genetic basis of cancer and heart failure in peripartum cardiomyopathy (PPCM). BACKGROUND PPCM manifests as heart failure late in pregnancy or postpartum in women without previous heart disease. METHODS Clinical history and cancer prevalence were evaluated in a cohort of 236 PPCM patients from Germany and Sweden. Exome sequencing assessed variants in 133 genes associated with cancer predisposition syndromes (CPS) and in 115 genes associated with dilated/hypertrophic cardiomyopathy (DCM/HCM) in 14 PPCM patients with a history of cancer, and in 6 PPCM patients without a history of cancer. RESULTS The prevalence of cancer was 16-fold higher (8.9%, 21 of 236 patients) in PPCM patients compared to agematched women (German cancer registry, Robert-Koch-Institute: 0.59%; p < 0.001). Cancer before PPCM occurred in 12 of 21 patients of whom 11 obtained cardiotoxic cancer therapies. Of those, 17% fully recovered cardiac function by 7 +/- 2 months of follow-up compared to 55% of PPCM patients without cancer (p 0.015). Cancer occurred after PPCM in 10 of 21 patients; 80% had left ventricular ejection fraction of >= 50% after cancer therapy. Whole-exome sequencing in 14 PPCM patients with cancer revealed that 43% (6 of 14 patients) carried likely pathogenic (Class IV) or pathogenic (Class V) gene variants associated with DCM/HCM in CPT2, DSP, MYH7, TTN, and/or with CPS in ATM, ERCCS, NBN, RECQL4, and SLX4. AR CPS variants affected DNA damage response genes. CONCLUSIONS Cardiotoxic cancer therapy before PPCM is associated with delayed full recovery. The high cancer prevalence in PPCM is linked to likely pathogenic/pathogenic gene variants associated with DCM/HCM and/or CPS/DNA damage response-related cancer risk. This may warrant genetic testing and screening for heart failure in pregnant women with a cancer history and screening for cancer in PPCM patients.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-2 av 2

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy